IndustryCompany release

Pfizer raises 2026 guidance after flat third-quarter sales and Innovent charge

🇺🇸 Pfizer Inc (PFE) · Tue 03 Nov 2026

Pfizer reported Q3 revenues of $16.6 billion and lifted full-year revenue and adjusted EPS guidance, while booking a $650 million charge for its Innovent Biologics in-licensing deal.

Pfizer reported third-quarter 2026 revenues of $16.6 billion on 3 November, roughly flat on the same period last year on an operational basis. Adjusted diluted earnings per share came to $0.87.

The company raised its full-year guidance. Revenue is now expected at $62.0 billion to $64.0 billion, and adjusted diluted EPS at $2.95 to $3.05.

The quarter included a $650 million in-process research and development charge linked to Pfizer's in-licensing agreement with Innovent Biologics. The item's headline also cites 32% growth in launched products, though the details behind that figure were not available to VigiEye.

Separately, Pfizer named Cecile Guegan as chief financial officer.

What it means for your team

  • Pfizer's raised guidance comes despite flat quarterly sales, with the company pointing to growth in launched products.
  • The $650 million in-process R&D charge shows the cost of the Innovent Biologics in-licensing deal, which market-access and portfolio teams may want to follow.
  • Details of the Innovent products and of the launched-product growth were not available, so teams should check Pfizer's full results materials before drawing conclusions.

Company's press release (SEC filing): Pfizer Inc ↗

Article written by VigiEye from the official source (Pfizer Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →